GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data

GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data is organized by Paradigm Medical Communications, LLC.

Release Date: March 28, 2024
Expiration Date: March 28, 2025

Description:
Let’s get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.

Learning Objectives:
Upon completion of this activity, participants should be able to:

• Describe the limitations of anti-VEGF therapy that have been illuminated by real-world analyses
• Evaluate real-world data demonstrating optimal use of dual inhibition therapy, including patient selection and dosing intervals
• Formulate treatment plans for patients with nAMD and DME that demonstrate appropriate integration and ongoing use of dual inhibition therapy, based on real-world evidence